Related Experiment Videos
Nonresponders to osteoporosis therapy.
1New Mexico Clinical Research & Osteoporosis Center, Inc., 300 Oak St. NE, Albuquerque, NM 87106, USA. LEWIECKI@aol.com
Summary
Osteoporosis treatment aims to reduce fracture risk. Bone density testing is a key surrogate measure, and a decrease exceeding the Least Significant Change may indicate nonresponse, prompting therapy adjustments.
Area of Science:
- Endocrinology
- Gerontology
- Bone Metabolism
Background:
- Osteoporosis therapy primarily aims to reduce fracture risk.
- Individual fracture risk assessment is challenging in clinical practice.
- Bone mineral density (BMD) testing serves as a surrogate marker for treatment efficacy.
Purpose of the Study:
- To define nonresponse to osteoporosis therapy using BMD changes.
- To highlight the importance of BMD monitoring in treatment assessment.
- To discuss potential causes and implications of nonresponse.
Main Methods:
- Utilizing bone mineral density (BMD) measurements.
- Defining nonresponse based on a decrease exceeding the Least Significant Change (LSC) at 95% confidence.
- Comparing BMD testing with biochemical markers for treatment responsiveness.
Main Results:
- A decrease in BMD greater than the LSC is proposed as a definition of nonresponse.
- BMD stability or increase correlates with fracture risk reduction.
- Nonresponse can stem from various factors including adherence, comorbidities, and drug efficacy.
Conclusions:
- The proposed definition of nonresponse aids in identifying patients needing intervention.
- BMD testing is a validated tool for assessing osteoporosis treatment response.
- Further research is needed to establish clinical guidelines for managing nonresponse.